glp -1 agonist Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review Current Insights, Advantages and Challenges

no major safety concerns were observed

Learn why it happens and discover Strive's Digest, a science-backed supplement for gentle, effective relief

The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss

- **Curb appetite:** Helping individuals feel full, potentially leading to reduced food intake